Literature DB >> 2421479

Topographical analysis of epitope relationships on the envelope glycoprotein of yellow fever 17D vaccine and the wild type Asibi parent virus.

N Cammack, E A Gould.   

Abstract

Monoclonal antibodies (MCA), with defined molecular specificity, were used in a competition binding enzyme-linked immunosorbent assay (ELISA) to locate the relative positions of the epitopes on the envelope glycoprotein of yellow fever 17D vaccine virus and its wild type parent virus, Asibi (AS). Five topographically distinct antigenic domains were defined on the E glycoprotein of the 17D vaccine. Three of these (A, B, and C) were represented by one MCA each, a fourth (D) was represented by two MCA, and a fifth domain (E) comprised a major cluster of at least five overlapping epitopes. Asibi virus also possessed domain E which is proposed to be a conserved antigenic region within the envelope glycoprotein of all flaviviruses. Domains A and C were not represented on Asibi virus and one epitope, situated proximal to the E domain, showed structural alterations in physical overlap. Functional activities were assigned to physically mapped epitopes by haemagglutination inhibition (HAI), virus neutralisation (N), and passive protection in mice. The HAI and N functions were not necessarily linked but only MCA with N activity were able to protect mice passively against lethal infection. All domains demonstrated a heterogeneous range of biological properties dependent upon the virus strain rather than the epitope.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421479     DOI: 10.1016/0042-6822(86)90298-9

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Identification of envelope protein epitopes that are important in the attenuation process of wild-type yellow fever virus.

Authors:  B K Sil; L M Dunster; T N Ledger; M R Wills; P D Minor; A D Barrett
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  Epitope mapping of dengue 1 virus E glycoprotein using monoclonal antibodies.

Authors:  E Simantini; K Banerjee
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

3.  Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing).

Authors:  H W Virgin; R Bassel-Duby; B N Fields; K L Tyler
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

4.  A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.

Authors:  Amanda E Calvert; Kandice L Dixon; Joseph Piper; Susan L Bennett; Brett A Thibodeaux; Alan D T Barrett; John T Roehrig; Carol D Blair
Journal:  Antiviral Res       Date:  2016-04-26       Impact factor: 5.970

5.  Characterization and modification of the carboxy-terminal sequences of bluetongue virus type 10 NS1 protein in relation to tubule formation and location of an antigenic epitope in the vicinity of the carboxy terminus of the protein.

Authors:  K Monastyrskaya; E A Gould; P Roy
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

6.  Determination of different antigenic sites on the adenovirus hexon using monoclonal antibodies.

Authors:  E Adám; I Nász; A Lengyel; J Erdei; J Fachet
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

7.  Isolation of a Potently Neutralizing and Protective Human Monoclonal Antibody Targeting Yellow Fever Virus.

Authors:  Michael P Doyle; Joseph R Genualdi; Adam L Bailey; Nurgun Kose; Christopher Gainza; Jessica Rodriguez; Kristen M Reeder; Christopher A Nelson; Prashant N Jethva; Rachel E Sutton; Robin G Bombardi; Michael L Gross; Justin G Julander; Daved H Fremont; Michael S Diamond; James E Crowe
Journal:  mBio       Date:  2022-04-14       Impact factor: 7.786

8.  Impact of yellow fever virus envelope protein on wild-type and vaccine epitopes and tissue tropism.

Authors:  Emily H Davis; Binbin Wang; Mellodee White; Yan-Jang S Huang; Vanessa V Sarathy; Tian Wang; Nigel Bourne; Stephen Higgs; Alan D T Barrett
Journal:  NPJ Vaccines       Date:  2022-03-23       Impact factor: 9.399

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.